A new positron emission tomography radiotracer has the potential to spot signs of Alzheimer’s disease years before symptoms appear.
That’s according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting, which wraps up on Tuesday, June 15. The chemical compound 18F-MK6240 has been shown to effectively measure increases in brain tau, a protein commonly found in healthy brain neurons.
Scientists see potential in using the new tracer to test the impact of emerging Alzheimer’s therapies. Read More
CAMBRIDGE, Mass. and TOKYO, June 07, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM™ (aducanumab-avwa) as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. Read More
Cerveau Technologies, Inc. today announced formation of its Scientific Advisory Board (SAB), comprised of top tier physicians and scientists from around the globe, spanning areas of expertise from chemistry, biology to medicine associated with the assessment and ultimate treatment of neurodegenerative diseases, such as Alzheimer’s Disease.
MK-6240 Users Group Meeting | Webinar #1 by Cerveau Technologies Inc
2020 Virtual Conference with world renowned Leaders and Scientists in the industry!
Rick Hiatt (Cerveau Technologies)
Oskar Hannson (Lund University)
Pedro Rosa-Neto (McGill University)
Keith Johnson (Harvard University)
Kuang Gong (Harvard University)
Christopher Rowe (University of Melbourne)
See the conference here
TORONTO–(BUSINESS WIRE)–Enigma Biomedical Group (EBG) today announced the appointment of Michael Reitermann to their Board of Directors effective December 1, 2019